Truist Financial analyst Joon Lee maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today. The company’s shares closed yesterday at $97.03.
Lee covers the Healthcare sector, focusing on stocks such as Argenx Se, Corcept Therapeutics, and Viking Therapeutics. According to TipRanks, Lee has an average return of 27.7% and a 53.33% success rate on recommended stocks.
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $133.92, a 38.02% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $180.00 price target.
Based on Axsome Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $104.76 million and a GAAP net loss of $64.6 million. In comparison, last year the company earned a revenue of $57.79 million and had a GAAP net loss of $62.2 million
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Axsome Therapeutics (AXSM) Company Description:
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Axsome Therapeutics announces AXS-12 achieves primary endpoint in ENCORE
- Needham adds Axsome to Conviction List, removes Blueprint
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics price target raised to $175 from $173 at Ladenburg
- Axsome Therapeutics price target raised to $118 from $106 at BofA
